Research Antibiotics, Vonoprazan Fumarate, 10 mg

Vonoprazan fumarate, 10 mg. Vonoprazan fumarate is a pyrole derivative and potassium-competitive acid blocker (P-CAB) that competitively blocks the potassium-binding site of gastric H(+),K(+)-ATPase, a key enzyme in the process of gastric acid secretion.

• Family: Microbiology
• CAS Number: 1260141-27-2
• Molecular Formula: C₁₇H₁₆FN₃O₂S – C₄H₄O₄
• Molecular Weight: 461.47
• Mechanism of Action: Vonoprazan fumarate Inhibits acid secretion by competitively blocking the potassium-binding site of gastric H(+),K(+)-ATPase. The compound can accumulate in acid environments and should provide a longer duration of inhibition due to an alkaline pKa of 9.06. In the presence of acid, this prodrug converts to its active form that covalently binds to certain cysteines in the luminal domain of gastric H(+),K(+)-ATPase.
• Storage Conditions: -20°C

Microbiology Applications

Helicobacter pylori (H. pylori) contributes to upper gastrointestinal diseases. Proton pump inhibitor (PPI)-based H. pylori eradication therapy has been shown to be effective for treatment of H. pylori, however, there have been an increase in Clarithromycin resistant strains, thus a more effective strategy is needed. Vonoprazan resulted in a stronger and more sustained acid suppression than PPI-based therapy. (Sakurai et al, 2017).

Eukaryotic Cell Culture Applications

The mode of action of Vonoprazan and Lansoprazole were studied using primary cultured rabbit gastric glands. Both compounds inhibited gastric acid formation in isolated gastric glands (IC₅₀) values, 0.30 and 0.76 μM, respectively. Vonoprazan had a longer and more potent antisecretory effect than Lansoprazole due to its high accumulation and slow clearance from gastric glands (Matsukawa et al, 2011).

Specifications

• Form: Powder
• Color: White or off-white powder
• Source: Synthetic

References

Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N (2011) A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 81(9):1145-1151 PMID 21371447 Shin JM et al (2011) Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J. Pharmacol. Exp. Ther. 339(2):412-420 PMID 21828261 Sakurai K et al (2017) Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol. 23(4):668-675 PMID 28216974 Sugano, K (2018) Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: Safety and clinical evidence to date. Therap. Adv. Gastroenterol. 11: 756283X17745776. PMID 29383028

Available Documents

• SDS-EU
• SDS
• Product Data Sheet

Made by an ISO 9001:2015 certified antibiotic manufacturer focused on creating antibiotics through fermentation.

By removing contamination and streamlining gene selection, these research antibiotics help scientists make discoveries in cell/plant biology, microbiology, virology, stem cell therapy, and cancer research. Specializing in the pharmaceutical and biotech research sectors.

These products are specifically designed for research use and are not approved for human or animal consumption. Not FDA approved.

Note: These chemicals are for research & laboratory use only. Your order will not be processed if you do not ship to a registered laboratory or research facility.

Please note: This product is not returnable.